Advanced in Cholangitis

Jorn M. Schattenberg

Saarbruecken, SL, DE 
Advanced in Cholangitis
Saarbruecken, SL, DE 
OverviewLocationsClinical Research

Overview

Jorn Schattenberg practices in Saarbruecken, Germany. Schattenberg is rated as an Advanced expert by MediFind in the treatment of Cholangitis. Their top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Colonoscopy.

Their clinical research consists of co-authoring 365 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Cholangitis.

Locations

Saarbruecken, SL, Germany
Other Locations
Mainz, RP, Germany
Homburg, SL, Germany
Mainz, RP, Germany
Gutenberg, RP, Germany
Mainz
Hirschhorn, RP, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Confocal Endoscopy to Diagnose the Intestinal Permeability in Patients With Compensated and Decompensated Liver Cirrhosis
Confocal Endoscopy to Diagnose the Intestinal Permeability in Patients With Compensated and Decompensated Liver Cirrhosis
Enrollment Status: Terminated
Publish Date: April 06, 2022
Intervention Type: Diagnostic test
Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis
Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: September 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)
Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)
Enrollment Status: Completed
Publish Date: May 16, 2017
Intervention Type: Dietary supplement, Other, Behavioral
Study Phase: Phase 2
View 5 Less Clinical Trials

365 Total Publications

Semaglutide targets MASH molecular pathways beyond weight loss.
Semaglutide targets MASH molecular pathways beyond weight loss.
Journal: Nature medicine
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Schattenberg's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile